CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Open-market sale Chief Accounting Officer sold 494 shares at $0.70 ($343)
- 4 Open-market sale Chief Accounting Officer sold 11,150 shares at $0.67 ($7,494)
- 4 Open-market sale Sinha Vikas sold 18,331 shares at $0.67 ($12,282)
- 4 Open-market sale General Counsel sold 8,869 shares at $0.67 ($5,942)
- 4 Open-market sale Chief Accounting Officer sold 5,792 shares at $0.67 ($3,881)
- 4 Open-market sale Chief Executive Officer sold 41,421 shares at $0.67 ($27,752)
- 4 Open-market sale Sinha Vikas sold 3,205 shares at $0.67 ($2,150)
- 4 Open-market sale Chief Executive Officer sold 9,500 shares at $0.67 ($6,369)
- 4 Open-market sale Chief Accounting Officer sold 901 shares at $0.67 ($604)
- 4 Open-market sale General Counsel sold 1,302 shares at $0.67 ($873)
- 4 Open-market sale Chief Accounting Officer sold 310 shares at $0.64 ($198)
- 4 Open-market sale General Counsel sold 424 shares at $0.64 ($271)
- 4 Open-market sale Sinha Vikas sold 961 shares at $0.64 ($614)
- 4 Open-market sale Chief Executive Officer sold 1,664 shares at $0.64 ($1,063)
- 4 Open-market sale Chief Accounting Officer sold 28,335 shares at $0.74 ($20,838)
- 4 Planned sale Sinha Vikas sold 2,490 shares at $1.63 ($4,061)
- 4 Planned sale Chief Executive Officer sold 7,071 shares at an average $1.67 ($11,794)
- 4 Planned sale Chief Accounting Officer sold 403 shares at $1.63 ($657)
- 4 Planned sale Chief Accounting Officer sold 715 shares at an average $1.56 ($1,116)
- 4 Planned sale Chief Executive Officer sold 8,581 shares at $1.58 ($13,558)
Page 7 of 19 · 363 filings